As of January 2023, our "Journal of Controversies Obstetrics & Gynecologyand Pediatrics" has been published under the Medihealth Academy to publish all articles, reviews and case reports on Pediatrics, especially in the field of Obstetrics and Gynecology. In order to facilitate the citation of the articles, to take our place in internationally respected indexes and to reach a wider readership, we will pay attention to the fact that our article language is only English in terms of acceptance.

Original Article
Evaluation of the effects of raloxifene treatment on uterus in asymptomatic postmenoposal patients by transvaginal Doppler ultrasonography
Aims: To evaluate the effects of raloxifene treatment on uterus in asymptomatic postmenopausal patients by Doppler transvaginal ultrasonography (TvUS).
Methods: Randomized controlled prospective study, 57 healthy postmenopausal asymptomatic patients, aged 45-60, who applied Okmeydanı Training and Research Hospital Obstetrics and Gynecology Outpatient Clinic between 2003-2004. Four patients were excluded from the study because they did not apply the treatment regularly. All of the patients were in natural menopause. They had not received any hormone replacement therapy before. Their body mass index (BMI) was below 30 kg/m2 and had no systemic diseases. The patients were divided into two groups as those who received raloxifene (n: 27) and those who did not (n: 26). Raloxifene was given 60 mg/day for 6 months. In all patients enrolled in the study, endometrial and uterine volume, pulsatility (PI) and resistance indices (RI) were evaluated by TvUS Doppler. Endometrial biopsies (EB) were obtained with pipelle at 0 and 6 months.
Results: There was no significant difference in terms of age, height, weight and BMI (p<0.05). Parity, menopause time and endometrial thickness were similar (p<0.05). EB results were similar (p<0.05). Uterine volumes at month 0 and 6 were similar (p<0.05). PI and RI were found to be similar in the right and left arteries at baseline (p<0.05). While PI and RI on the right side were similar at 6 months, left uterine artery PI was found to be significantly higher in the treated group. Left uterine artery RI was similar.
Conclusion: Raloxifene treatment neither did stimulate the endometrium, nor increased the uterine volume or uterine blood flow. It did not have any stimulating effect on the uterine tissue.

1. Brambilla DJ, McKinlay SM. A prospective study of factorsaffecting age at menopause. J Clin Epidemiol. 1989;42(11):1031-1039.doi:10.1016/0895-4356(89)90044-9
2. Speroff L. Menopause and Postmenapausal Hormone therapy. In: GlassRH, Kasa NG, Speroff L (Eds). Clinical Gynecologic Endocrinology andInfertility. 5th ed. Baltimore;Williams and Wilkins, 1996:583-649.
3. Gokmen Karasu AF, Ates S, Gurbuz T, Sahin N, Takmaz T, Aydin S.&ldquo;A clinico-pathological study of transvaginal endometrial thicknessmeasurement in asymptomatic postmenopausal patients andpatients with postmenopausal bleeding&rdquo;. Gynecol Obstet Reprod Med.2019;25(2): 85-88. doi:10.21613/GORM.2018.851.
4. Gold EB. The timing of the age at which natural menopause occurs.Obstet Gynecol Clin North Am. 2011;38(3):425-440. doi:10.1016/j.ogc.2011.05.002
5. ACOG Practice Bulletin No. 141: management of menopausalsymptoms. Obstet Gynecol. 2014;123(1):202-216. doi:10.1097/01.AOG.0000441353.20693.78
6. Vehid S, Aran SN, K&ouml;ksal S, Işiloglu H, Senocak M. The prevalenceand the age at the onset of menopause in Turkish women in rural area.Saudi Med J. 2006;27(9):1381-1386.
7. Ozdemir O, C&ouml;l M. The age at menopause and associated factors at thehealth center area in Ankara, Turkey. Maturitas. 2004;49(3):211-219.doi:10.1016/j.maturitas.2004.01.013
8. Atas&uuml; T, Tekin Hİ. Menapozun semptomları. İ&ccedil;inde: Atas&uuml; T,Edit&ouml;rler. Menapoz Tedavisi ve Kanser. 1. Baskı. İstanbul: Nobel TıpKitapevi;2001:95-109.
9. Hassa H, &Uuml;nl&uuml; C, Yakın K, ve ark. Hormon replasman tedavisi,İ&ccedil;inde: Ert&uuml;ngealp E, Seyisoğlu H. (ed) Menopoz ve osteoporoz.İstanbul;Menopoz ve Osteoporoz Derneği, 2000:142-300.
10. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits ofestrogen plus progestin in healthy postmenopausal women: principalresults From the Women&rsquo;s Health Initiative randomized controlledtrial. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321.
11. Francucci CM, Romagni P, Boscaro M. Raloxifene: bone andcardiovascular effects. J Endocrinol Invest. 2005;28(10):85-89.
12. Wei GS, Jackson JL, Hatzigeorgiou C, Tofferi JK. Osteoporosismanagement in the new millennium. Prim Care. 2003;30(4):711-vii.doi:10.1016/s0095-4543(03)00090-3
13. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracturerisk in postmenopausal women with osteoporosis treated withraloxifene: results from a 3-year randomized clinical trial. MultipleOutcomes of Raloxifene Evaluation (MORE) Investigators. JAMA.1999;282(7):637-645. doi:10.1001/jama.282.7.637
14. Anzano MA, Peer CW, Smith JM, et al. Chemoprevention ofmammary carcinogenesis in the rat: combined use of raloxifeneand 9-cis-retinoic acid. J Natl Cancer Inst. 1996;88(2):123-125.doi:10.1093/jnci/88.2.123
15. Messalli EM, Mainini G, Scaffa C, et al. Raloxifene therapyinteracts with serum osteoprotegerin in postmenopausal women.Maturitas.2007;56(1):38-44. doi:10.1016/j.maturitas.2006.05.007
16. Reginster JY, Devogelaer JP. Raloxifene reduces fractures inpostmenopausal women with osteoporosis. Clin Orthop Relat Res.2006;443:48-54. doi:10.1097/01.blo.0000200234.99436.24
17. Stuart B, Drumm J, FitzGerald DE, Duignan NM. Fetal bloodvelocity waveforms in normal pregnancy. Br J Obstet Gynaecol.1980;87(9):780-785. doi:10.1111/j.1471-0528.1980.tb04613.x
18. Gosling R, King D. Ultrasonic Angiography. In: Hascus AW,Adamson L, eds. Arteries and Veins, Edinburg: ChurchillLivingstone;1975: 61-98
19. Pourcelot L. Applications cliniquesde l&rsquo; examen Dopplertranscutane. In: Pourcelot L, ed: Seminaire INSERM. Paris: editionsINSERM;1974: 213-240
20. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifeneon bone mineral density, serum cholesterol concentrations, anduterine endometrium in postmenopausal women. N Engl J Med.1997;337(23):1641-1647. doi:10.1056/NEJM199712043372301
21. Fleischer AC, Appelbaum MI, Parsons AK. Transvaginal sonographyof the normal endometrium. In: Fleischer AC, Kurjak A, GranbergS, editors. Ultrasound and the endometrium. New York: Parthenon,1997: 1-15.
22. Karlsson B, Granberg S, Wikland M, et al. Transvaginalultrasonography of the endometrium in women withpostmenopausal bleeding--a Nordic multicenter study. Am J ObstetGynecol. 1995;172(5):1488-1494. doi:10.1016/0002-9378(95)90483-2
23. Cummings SR, Eckert S, Krueger KA, et al. The effect ofraloxifene on risk of breast cancer in postmenopausal women:results from the MORE randomized trial. Multiple Outcomes ofRaloxifene Evaluation. JAMA. 1999;281(23):2189-2197. doi:10.1001/jama.281.23.2189
24. de Azevedo GD, do Prado MF, Ferriani RA, et al. Raloxifene therapydoes not affect uterine blood flow in postmenopausal women:a transvaginal Doppler study. Maturitas. 2004;47(3):195-200.doi:10.1016/S0378-5122(03)00280-9
25. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW,Parsons AK. A 12-month comparative study of raloxifene, estrogen,and placebo on the postmenopausal endometrium. Obstet Gynecol.2000;95(1):95-103. doi:10.1016/s0029-7844(99)00502-5
26. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen onuterus and ovaries of postmenopausal women in a randomisedbreast cancer prevention trial. Lancet. 1994;343(8909):1318-1321.doi:10.1016/s0140-6736(94)92466-x
27. Harris ST, Genant HK, Baylink DJ, et al. The effects of estrone (Ogen)on spinal bone density of postmenopausal women. Arch Intern Med.1991;151(10):1980-1984.
28. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene andcardiovascular events in osteoporotic postmenopausal women:four-year results from the MORE (Multiple Outcomes of RaloxifeneEvaluation) randomized trial. JAMA. 2002;287(7):847-857.doi:10.1001/jama.287.7.847
29. Bourne T, Hillard TC, Whitehead MI, Crook D, Campbell S.Oestrogens, arterial status, and postmenopausal women. Lancet.1990;335(8703):1470-1471. doi:10.1016/0140-6736(90)91505-5
30. Achiron R, Lipitz S, Frenkel Y, Mashiach S. Endometrial bloodflow response to estrogen replacement therapy and tamoxifen inasymptomatic, postmenopausal women: a transvaginal Dopplerstudy. Ultrasound Obstet Gynecol. 1995;5(6):411-414. doi:10.1046/j.1469-0705.1995.05060411.x
31. Post MS, van der Mooren MJ, van Baal WM, Neele SJ, NetelenbosJC, Kenemans P. Raloxifene reduces impedance to flow withinthe uterine artery in early postmenopausal women: a 2-yearrandomized, placebo-controlled, comparative study. Am J ObstetGynecol. 2001;185(3):557-562. doi:10.1067/mob.2001.117340
32. Fug&egrave;re P, Scheele WH, Shah A, Strack TR, Glant MD, Jolly E. Uterineeffects of raloxifene in comparison with continuous-combinedhormone replacement therapy in postmenopausal women. Am JObstet Gynecol. 2000;182(3):568-574. doi:10.1067/mob.2000.104768
Volume 1, Issue 2, 2023
Page : 30-35